Log in
NASDAQ:PHAS

PhaseBio Pharmaceuticals Stock Forecast, Price & News

$3.41
-0.24 (-6.58 %)
(As of 09/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.35
Now: $3.41
$3.71
50-Day Range
$3.17
MA: $3.74
$4.32
52-Week Range
$2.60
Now: $3.41
$8.49
Volume248,231 shs
Average Volume534,603 shs
Market Capitalization$100.06 million
P/E RatioN/A
Dividend YieldN/A
Beta1.57
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. The company has an agreement with Viamet Pharmaceuticals Holdings, LLC and Selenity Pharmaceuticals (Bermuda) Ltd. to develop PB6440, a lead development compound for treatment of resistant hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHAS
CUSIPN/A
CIKN/A
Phone610-981-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.36 million
Book Value$2.09 per share

Profitability

Net Income$-39,250,000.00
Net Margins-2,310.60%

Miscellaneous

Employees40
Market Cap$100.06 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$3.41
-0.24 (-6.58 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PHAS News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions

How has PhaseBio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PHAS stock has increased by 8.9% and is now trading at $3.41.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of PhaseBio Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for PhaseBio Pharmaceuticals
.

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for PhaseBio Pharmaceuticals
.

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) issued its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.46. PhaseBio Pharmaceuticals had a negative net margin of 2,310.60% and a negative return on equity of 124.88%.
View PhaseBio Pharmaceuticals' earnings history
.

What price target have analysts set for PHAS?

5 analysts have issued 1-year price objectives for PhaseBio Pharmaceuticals' stock. Their forecasts range from $10.00 to $18.00. On average, they expect PhaseBio Pharmaceuticals' share price to reach $14.25 in the next year. This suggests a possible upside of 317.9% from the stock's current price.
View analysts' price targets for PhaseBio Pharmaceuticals
.

Who are some of PhaseBio Pharmaceuticals' key competitors?

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Viking Therapeutics (VKTX), VBI Vaccines (VBIV), Amarin (AMRN), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO) and Nabriva Therapeutics (NBRV).

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the following people:
  • Mr. Jonathan P. Mow, Pres, CEO & Director (Age 55, Pay $678.78k)
  • Mr. John P. Sharp, Chief Financial Officer (Age 55, Pay $548.51k)
  • Dr. John S. Lee, Chief Medical Officer (Age 52, Pay $581.5k)
  • Mr. Kristopher L. Hanson, VP, Head of Legal & Corp. Sec. (Age 48)
  • Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 55)

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

Who are PhaseBio Pharmaceuticals' major shareholders?

PhaseBio Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Bridgeway Capital Management Inc. (0.52%), Sabby Management LLC (0.27%), Charles Schwab Investment Management Inc. (0.14%), Nuveen Asset Management LLC (0.11%), First Trust Advisors LP (0.10%) and Goldman Sachs Group Inc. (0.10%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras.
View institutional ownership trends for PhaseBio Pharmaceuticals
.

Which institutional investors are selling PhaseBio Pharmaceuticals stock?

PHAS stock was sold by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Sabby Management LLC, Goldman Sachs Group Inc., and Nuveen Asset Management LLC.
View insider buying and selling activity for PhaseBio Pharmaceuticals
.

Which institutional investors are buying PhaseBio Pharmaceuticals stock?

PHAS stock was purchased by a variety of institutional investors in the last quarter, including Leap Investments LP, Wedbush Securities Inc., Charles Schwab Investment Management Inc., Bank of America Corp DE, and First Trust Advisors LP. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson, and Venture Advisors Iii Hatteras.
View insider buying and selling activity for PhaseBio Pharmaceuticals
.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $3.41.

How big of a company is PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals has a market capitalization of $100.06 million and generates $2.36 million in revenue each year. The company earns $-39,250,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. PhaseBio Pharmaceuticals employs 40 workers across the globe.

What is PhaseBio Pharmaceuticals' official website?

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.